Most recent
-
31 Aug 2014: The bid from Pfizer, now active again, has caused widespread anger. But another takeover 10 years ago was a different story, writes Julia Kollewe -
31 Jul 2014:
Britain's second-largest drugmaker, which fended off a takeover approach from US rival Pfizer, highlighted the progress made replenishing its pipeline of new therapies
-
27 Jul 2014:
Business secretary Vince Cable has promised to strengthen takeover rules following Pfizer's attempt to buy AstraZeneca. But foreigners are increasingly in control of everything from Premier League football to political party strategy
-
14 Jul 2014: International firms often shift their HQs to exploit tax regimes - a process particularly attractive at present to US companies
-
9 Jul 2014:
US pharma group climbs down after chief executive reportedly said investors in Dublin-based rival were 'generally supportive' of company's offer
-
8 Jul 2014:
Business secretary looking at ways to enforce pledges made by companies in wake of US group Pfizer's offer for AstraZeneca
-
8 Jul 2014: US pharma giant seeks to buy Dublin-based Shire to optimise tax in move reminiscent of Pfizer's failed pursuit of AstraZeneca
-
26 Jun 2014: Surprise decision by FDA over olaparib could threaten drugmaker's effort to fight off Pfizer takeover
-
20 Jun 2014:
Approach is second by an American drugmaker for a UK-listed firm in two months following Pfizer's failed bid for AstraZeneca
-
3 Jun 2014: Anglo-Swedish firm shows off progress on lung and ovarian cancer treatments at centre of defence against Pfizer takeover bid
-
27 May 2014: Anglo-Swedish group's stock has fallen more than 10% since the collapse of talks with New York-based drug firm
-
26 May 2014:
AstraZeneca chief Pascal Soriot has seen off a takeover effort led by Pfizer boss Ian Read, but now both men have work to do
-
26 May 2014:
US group formally concedes that its nearly £70bn bid to create world's largest pharmaceutical business has failed
-
25 May 2014: The US pharmaceuticals group's takeover bid looks moribund – but not every shareholder wants the talking to stop, writes Rupert Neate
-
23 May 2014:
Trying to engineer new talks, it's as if BlackRock and Schroders are giving AstraZeneca three months to cure cancer or else
1-15 of 176 for Pfizer
;